![]() |
Name |
(1R,5S)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one
|
Molecular Formula | C10H14O | |
IUPAC Name* |
(1R,5S)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one
|
|
SMILES |
CC1=CC(=O)[C@@H]2C[C@@H]1C2(C)C
|
|
InChI |
InChI=1S/C10H14O/c1-6-4-9(11)8-5-7(6)10(8,2)3/h4,7-8H,5H2,1-3H3/t7-,8-/m0/s1
|
|
InChIKey |
DCSCXTJOXBUFGB-YUMQZZPRSA-N
|
|
Synonyms |
VERBENONE; ZINC100020986; (1R,5S)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one
|
|
CAS | NA | |
PubChem CID | 6973628 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 150.22 | ALogp: | 1.6 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 17.1 | Aromatic Rings: | 3 |
Heavy Atoms: | 11 | QED Weighted: | 0.519 |
Caco-2 Permeability: | -4.574 | MDCK Permeability: | 0.00002990 |
Pgp-inhibitor: | 0.095 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.708 |
30% Bioavailability (F30%): | 0.004 |
Blood-Brain-Barrier Penetration (BBB): | 0.963 | Plasma Protein Binding (PPB): | 69.02% |
Volume Distribution (VD): | 1.595 | Fu: | 26.52% |
CYP1A2-inhibitor: | 0.085 | CYP1A2-substrate: | 0.287 |
CYP2C19-inhibitor: | 0.183 | CYP2C19-substrate: | 0.835 |
CYP2C9-inhibitor: | 0.066 | CYP2C9-substrate: | 0.786 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.636 |
CYP3A4-inhibitor: | 0.019 | CYP3A4-substrate: | 0.279 |
Clearance (CL): | 13.717 | Half-life (T1/2): | 0.544 |
hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.128 |
Drug-inuced Liver Injury (DILI): | 0.377 | AMES Toxicity: | 0.015 |
Rat Oral Acute Toxicity: | 0.389 | Maximum Recommended Daily Dose: | 0.207 |
Skin Sensitization: | 0.591 | Carcinogencity: | 0.622 |
Eye Corrosion: | 0.975 | Eye Irritation: | 0.977 |
Respiratory Toxicity: | 0.961 |